• Do Utah and the UK Prove Clinical Oversight Is the Future of Medical Cannabis
    Nov 18 2026

    As daily cannabis use climbs to roughly 1.2 million people in Great Britain (Forbes), retail pharmacy giant Boots is launching its SureLeaf online prescription service across roughly 1,800 UK locations to offer affordable medical cannabis flower and oil starting at £40—a mainstream breakthrough modeled directly on clinical pharmacy integration (MJBizDaily; The Telegraph). This rollout mirrors the clinical blueprint pioneered in Utah, where state law replaces traditional retail "budtenders" with licensed Pharmacy Medical Providers (PMPs) who review patient medical histories, screen for CYP-mediated drug interactions, and guide individualized dose titration (Pharmacy Times; Cannabis Industry Journal). Together, Utah's established framework and the UK's high-street expansion validate a crucial lesson underscored by pharmacy policy experts (Pharmacy Times): embedding licensed pharmacists into regulated cannabis distribution—rather than sidelining them as Canada did (Pharmacy Times)—legitimizes the plant as a safe, standardized therapeutic, protects vulnerable patients, and unlocks sustainable mainstream market growth.



    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
    Show More Show Less
    10 mins
  • Abstrax Revolutionizes Terpenes, Hops, and Cannabis Innovation
    Nov 11 2026

    Blunt Business welcomes back Kevin Koby, CEO and co-founder of Abstrax Tech. Returning to the show five and a half years after his first appearance, Koby discusses his transition from Chief Scientific Officer to CEO and highlights how Abstrax Tech has evolved from a terpene distributor to an industry leader in aroma chemistry and analytical research.



    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
    Show More Show Less
    37 mins
  • DEA Rescheduling and Form 225 Compliance Overview
    Nov 4 2026

    Blunt Business speaks with Jonathan Wachs regarding the DEA’s proposed Schedule 3 rescheduling process, the launching of the Form 225 registration portal for medical cannabis operators, and the regulatory and compliance challenges facing businesses in dual-use markets.

    The Drug Enforcement Administration (DEA) has launched its Schedule 3 registration portal using Form 225 for medical cannabis manufacturers, distributors, and analytical laboratories. Applying through the system involves substantial non-refundable annual registration fees, set at $3,699 for manufacturers, $1,850 for distributors, and $296 for analytical labs.

    Given the complexity of the disclosures required on Form 225, Wachs advises operators to retain legal counsel to ensure accurate filings and navigate potential legal exposures.




    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
    Show More Show Less
    37 mins
  • Cannabis Drinks Spark a High-Stakes Battle Over America’s Tap
    Oct 28 2026

    Driven by consumers seeking hangover-free buzzes, the rapid surge in hemp-derived THC beverages has triggered a high-stakes civil war across the US alcohol landscape.

    Traditional brewers and distillers—reeling from a historic downturn in conventional booze sales—are aggressively lobbying for strict regulatory caps as low as 0.4 mg of THC per beverage to shut down competition, while liquor distributors and retailers fight to protect a booming category that generates over $1 billion annually and threatens to slice up to 20% off their bottom lines if outlawed.

    As mainstream liquor store shelves increasingly swap out craft beer and spirits for rapid-acting seltzers, alcohol heavyweights find themselves sharply divided: some push to force all cannabinoid drinks behind dispensary counters, while conglomerates like Tilray lean into the disruption by producing both craft beer and THC cocktails to meet evolving consumer tastes.



    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
    Show More Show Less
    24 mins
  • Flavoring the Future: Inside True Terpenes' Cannabis Revolution
    Oct 21 2026

    True Terpenes CEO Daniel Cook joins Blunt Business to discuss the company's innovative "Loud Flavors" platform, designed to provide accessible, nostalgia-driven entry points for new cannabis consumers.

    We explore rigorous toxicology compliance, co-funded university research at Johns Hopkins and UCLA, data-driven market insights across legal states, and the evolving business implications of federal cannabis rescheduling.1



    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
    Show More Show Less
    37 mins
  • Last Call for Legal THC: Mainstream Media Sounds the Alarm on the Looming Federal Hemp Ban
    Oct 7 2026

    Major outlets like PBS NewsHour, NPR, and Forbes are turning their spotlight onto an impending regulatory cliff that threatens to dismantle America's $28 billion hemp-derived THC market. As the year-end countdown accelerates, national reporting is moving beyond niche cannabis circles to expose how closing the 2018 Farm Bill's cannabinoid loophole could wipe out retail shelves overnight.

    From the rapid rise of mainstream THC-infused seltzers to severe financial fallout—such as frozen bank accounts and abruptly called commercial loans—this surge in high-profile coverage is transforming an obscure legislative showdown into an urgent economic talking point for mainstream consumers and businesses alike.



    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
    Show More Show Less
    22 mins
  • Massachusetts Cannabis on the Brink: 18,000 Jobs at Stake as Voters Defend Legalization
    Sep 30 2026

    Massachusetts is at the center of the nation's cannabis conversation as a looming repeal ballot initiative threatens the livelihoods of nearly 18,000 workers across the state's marijuana industry. Despite the existential risk to these businesses and local jobs, recent polling shows that Massachusetts voters overwhelmingly oppose repealing adult-use cannabis, signaling strong public commitment to maintaining the regulated market.

    This critical fight for market stability in the Commonwealth unfolds alongside wider industry maturation, where even traditional commercial insurers are pushing for broader cannabis access to capture demand in states where legal cannabis has firmly taken root.



    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
    Show More Show Less
    26 mins